1. Home
  2. RBBN vs IFRX Comparison

RBBN vs IFRX Comparison

Compare RBBN & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ribbon Communications Inc.

RBBN

Ribbon Communications Inc.

HOLD

Current Price

$2.01

Market Cap

355.8M

Sector

Technology

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.74

Market Cap

303.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBBN
IFRX
Founded
1997
2007
Country
United States
Germany
Employees
3080
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
355.8M
303.4M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
RBBN
IFRX
Price
$2.01
$1.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$4.67
$6.25
AVG Volume (30 Days)
784.5K
1.3M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
170.97
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.97
N/A
Revenue Next Year
$6.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.83
$0.74
52 Week High
$4.24
$2.95

Technical Indicators

Market Signals
Indicator
RBBN
IFRX
Relative Strength Index (RSI) 37.02 36.03
Support Level $1.83 $0.87
Resistance Level $2.86 $1.94
Average True Range (ATR) 0.14 0.15
MACD -0.00 -0.04
Stochastic Oscillator 5.49 3.97

Price Performance

Historical Comparison
RBBN
IFRX

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: